1 November 2017 - Pediapharm is very pleased to announce Health Canada's notice of compliance (approval) for Cuvposa (Glycopyrrolate oral solution 1 mg/5 mL) which is indicated to reduce chronic severe drooling in patients aged 3-18 years with neurologic conditions associated with problem drooling (e.g. cerebral palsy).

Chronic drooling, or excessive production of saliva (sialorrhea), is a common condition found in children with CP but it may also be diagnosed in patients with other neurological disorders (i.e. severe developmental delay, autism spectrum disorders, sensory impairments, traumatic brain injuries as well as neurogenetic and metabolic disorders.)

Read Pediapharm press release